The StradobodyTM Platform

The StradobodyTM platform represents a novel way to make antibody-mimetics, generating monoclonal antibody-like compounds that are more effective than mAbs when directed against cancer and inflammatory disease targets. Funded in part under a competitively obtained NCI contract, Gliknik has made a series of stradobodiesTM with 100-fold greater potency compared to the corresponding monoclonal antibody. Gliknik expects the stradobodyTM platform to be applicable to enhancing any normal cancer monoclonal antibody that induces ADCC.